RE: Results19 Sep 2023 17:20
Just listened in to the meeting.
No real mention about share price. A lot of talk surrounding digital platform.
Its clear revenue from new products is low. I think a figure of £122,000 was mentioned i heard correctly.
No mention of NHS approval for tests.
Regular stuff
Well cashed for expansion and debt free.
New article coming out in the telegraph
Ongoing re occurring revenue from Covid!
Strategic partnerships to be explored but No acquisitions planned for 2023.
Concentration on grow and educating people in wellness testing etc.
Focus on Boots and no mention of new contracts.
Didn’t hear her intention to buy shares but I missed first 10mins!
Overall quite as expected and everything we basically new covered.